Section 414.701 - [Effective 1/1/2025] Commission may not rely solely on comparative effectiveness research(1) As used in this section, "peer-reviewed medical literature" has the meaning given that term in ORS 414.690.(2) The Health Evidence Review Commission, in ranking health services or developing guidelines under ORS 414.690 or in assessing medical technologies under ORS 414.698, and the Pharmacy and Therapeutics Committee, in considering a recommendation for a drug to be included on any preferred drug list or on the Practitioner-Managed Prescription Drug Plan: (a) May not rely solely on the results of comparative effectiveness research but must evaluate a range of research and analysis, including peer-reviewed medical literature that: (A) Studies health outcomes that are priorities for persons with disabilities who experience specific diseases or illnesses, through surveys or other methods of identifying priority outcomes for individuals who experience the diseases or illnesses;(B) Studies subgroups of patients who experience specific diseases or illnesses, to ensure consideration of any important differences and clinical characteristics applicable to the subgroups; and(C) Considers the full range of relevant, peer-reviewed medical literature and avoids harm to patients caused by undue emphasis on evidence that is deemed inconclusive of clinical differences without further investigation.(b) May consider research or analyses that reference a quality of life in general measure only if: (A) The staff of the commission includes an individual who:(i) Is trained in identifying bias and discrimination in medical research and analyses;(ii) Is not involved in research evaluation and recommendations for a given condition treatment pair on the prioritized list subject to the commission's review; and(iii) Determines that any of a researcher's conclusions and analyses about the value or cost-effectiveness of a treatment, that were relied upon by the staff of the commission in making a recommendation regarding the treatment, did not rely upon and were not influenced by the quality of life in general measure; and(B) All references to the quality of life in general measure are redacted from the research or analyses before the research or analyses are presented to the commission or to any advisory committee or subcommittees used or consulted by the commission.(3) The commission may not contract with a single vendor to provide or compile research and analysis that is considered by the commission, and the commission shall publicly disclose, regarding vendors providing or compiling research or analysis to the commission: (a) The vendors' funding sources; and(b) Any conflicts of interest that a vendor may have with respect to the research and analysis provided.Amended by 2024 Ch. 18,§ 4, eff. 1/1/2025.This section is set out more than once due to postponed, multiple, or conflicting amendments.